Vinay Prasad Reinstated as FDA Biologics Head

Dr. Vinay Prasad, who resigned as head of the FDA’s Center for Biologics Evaluation and Research in late July after facing pressure from right-wing activists and criticism over his handling of Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy, has been reinstated to his position. His resignation followed a campaign led by far-right influencer Laura Loomer, who accused him of undermining President Trump's health agenda and criticized his political views. The controversy escalated after the FDA temporarily suspended Sarepta’s gene therapy shipments due to reports of patient deaths, prompting backlash from both industry and political circles. Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary advocated for Prasad's return, leading the FDA to request his reinstatement. Prasad’s case underscores the ongoing tensions and political influence affecting leadership within the FDA during the Trump administration. The situation also highlights the challenges posed by external pressures from political actors and the pharmaceutical industry.